Currently Viewing:
Newsroom
Currently Reading
Pfizer Announces Phase 3 Trial for Atopic Dermatitis Treatment
December 15, 2017 – Samantha DiGrande
Majority of Women With Breast Cancer Surgery Did Not Feel Fully Informed of Treatment Options
December 15, 2017 – Jaime Rosenberg
AJMC® in the Press, December 15, 2017
December 15, 2017 – AJMC Staff
What We're Reading: Medicare Lab Testing; CHIP Deadline; AMA Expands Diabetes Efforts
December 15, 2017 – AJMC Staff
5 Key Takeaways From ASH 2017
December 15, 2017 – Surabhi Dangi-Garimella, PhD
This Week in Managed Care: December 15, 2017
December 15, 2017
What We're Reading: Medical Device Tax; Marijuana and Vaping; Birth Control Without Prescriptions
December 14, 2017 – AJMC Staff
Study Finds Breathing Retraining Associated With Quality of Life Improvement for Patients With Asthma
December 14, 2017 – Laura Joszt
Rain and Pain Not Related, Harvard Researchers Say
December 13, 2017 – Allison Inserro

Scientists Find Brake for Protein Shell of HIV, Blocking Infection

Allison Inserro
Researchers find brake mechanism that prevents an essential shell from forming on virus that causes AIDS.

 
Researchers have discovered a "brake" that interferes with HIV's development into an infectious agent. This mechanism prevents the capsid (the protein shell covering the virus) from forming.

The study, funded by the National Institutes of Health (NIH), was led by the University of Delaware (UD) and the University of Pittsburgh School of Medicine. Other participating institutions included the University of Illinois, the National Cancer Institute, DFH Pharma, and Vanderbilt University Medical Center. The findings were published in Nature Communications.

"People used to be fixated on the static structures of viruses, but they are not rock solid," Tatyana Polenova, PhD, professor in UD's Department of Chemistry and Biochemistry, said in a statement. She said viruses like HIV and their related protein and nucleic acid molecules are constantly expanding and shrinking. In the study, the movements of the virus molecules were measured experimentally and simulated in quadrillionths of a second—much faster than the blink of an eye.

A cascade of events occurs as the HIV virus develops, affecting its structure and ability to infect. But in this case, protein building blocks get cut from a larger, master protein called Gag.

By integrating state-of-the-art techniques, including solid-state and solution nuclear magnetic resonance (NMR), high-end computer simulations, and cryo-electron microscopy, the researchers discovered how the final step in the maturation of the virus occurs—a process in which a noninfectious immature virion turns into an infectious virus particle.

The team discovered that a key peptide, spacer peptide 1 (SP1), has to be in a highly mobile structure to be cut by the virus protease, the enzyme that acts like a cleaver. In simulations, the peptide resembles a thin, yarn-like strand attached to corkscrews of curled ribbons in constant motion.

Once the SP1 peptide is cut, the HIV virus forms its protective capsid and becomes infectious. To stop the process, the anti-HIV drug bevirimat was shown to interact with the SPI peptide, preventing the development of the virus' capsid coat.

Finding potential drug targets to stop HIV from becoming infectious by disrupting the maturation process is an ongoing research goal.

 
 


 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!